Literature DB >> 28948454

Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

Jeffrey Patterson-Fortin1, Alison R Moliterno2.   

Abstract

The myeloproliferative neoplasms polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) display distinct clinical and pathologic features but are characterized by mutations in JAK2, MPL, and CALR leading to activation of the JAK-STAT pathway. This review addresses the pathogenesis and mechanisms of these mutant alleles and the unique interactions of both of age and gender.

Entities:  

Keywords:  Aging; JAK2; Myeloproliferative neoplasms; Pathogenesis; Sex differences

Mesh：

Substances：

Year:  2017        PMID： 28948454     DOI： 10.1007/s11899-017-0411-0

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  72 in total

1.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

4.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

Review 5.  The renaissance of interferon therapy for the treatment of myeloid malignancies.

Authors:  Jean-Jacques Kiladjian; Ruben A Mesa; Ronald Hoffman
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

6.  Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors:  Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal:  Lancet Oncol       Date:  2016-12-02       Impact factor: 41.316

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  Two clinical phenotypes in polycythemia vera.

Authors:  Jerry L Spivak; Michael Considine; Donna M Williams; Conover C Talbot; Ophelia Rogers; Alison R Moliterno; Chunfa Jie; Michael F Ochs
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

9.  Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.

Authors:  Marito Araki; Yinjie Yang; Nami Masubuchi; Yumi Hironaka; Hiraku Takei; Soji Morishita; Yoshihisa Mizukami; Shin Kan; Shuichi Shirane; Yoko Edahiro; Yoshitaka Sunami; Akimichi Ohsaka; Norio Komatsu
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

10.  Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Authors:  Paola Guglielmelli; Annalisa Pacilli; Giada Rotunno; Elisa Rumi; Vittorio Rosti; Federica Delaini; Margherita Maffioli; Tiziana Fanelli; Alessandro Pancrazzi; Daniela Pietra; Silvia Salmoiraghi; Carmela Mannarelli; Annalisa Franci; Chiara Paoli; Alessandro Rambaldi; Francesco Passamonti; Giovanni Barosi; Tiziano Barbui; Mario Cazzola; Alessandro M Vannucchi
Journal:  Blood       Date:  2017-03-28       Impact factor: 25.476
View more
  1 in total

Review 1.  Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?

Authors:  Przemyslaw J Kotyla
Journal:  Biomed Res Int       Date:  2018-05-10       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.